Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

Poster highlights 6-month follow-up data from the ongoing Phase 2 trial of NDV-01 in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Relmada plans to advance NDV-01, a sustained release intravesical formulation of gemcitabine/docetaxel (Gem/Doce), into Phase 3 studies in two indications in H1 2026 Company is focused on high-risk NMIBC and intermediate-risk NMIBC, representing about 80% of new NMIBC cases every year, or about 54,000 people in the United States CORAL GABLES, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced that the previously disclosed 6-month follow-up data from the ongoing Phase 2 study of NDV-01, a sustained release, intravesical formulation of gemcitabine and docetaxel (Gem/Doce), in development for non-muscle invasive bladder cancer (NMIBC) will be presented in a poster at the Society of Urologic Oncology 26th Annual Meeting (SUO 2025).

GlobeNewsWire • Dec 3, 2025

Relmada Therapeutics, Inc. (RLMD) Q3 2025 Earnings Call Transcript

Relmada Therapeutics, Inc. ( RLMD ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Sergio Traversa - CEO & Director Raj Pruthi - Chief Medical Officer of Urology Maged Shenouda - Chief Financial Officer Conference Call Participants Brian Ritchie - Lifesci Advisors, LLC Uy Ear - Mizuho Securities USA LLC, Research Division Presentation Operator Good afternoon, and welcome to Relmada Therapeutics Third Quarter 202 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for replay on the Relmada website.

Seeking Alpha • Nov 14, 2025

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

Positive 9-month follow-up data for NDV-01 showed a 92% overall response rate at any time in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety

GlobeNewsWire • Nov 13, 2025

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

CORAL GABLES, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, November 13, 2025 at 4:30 PM ET to discuss financial results for the third quarter ended September 30, 2025 and recent business progress.

GlobeNewsWire • Nov 7, 2025

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

Announces NDV-01 9-Month Follow-up Safety and Efficacy Data in NMIBC FDA feedback supports 2 potential registrational trials – 1) a registrational trial in 2nd line refractory BCG-unresponsive NMIBC, and 2) a randomized controlled trial in intermediate-risk NMIBC. FDA Feedback also confirms no additional non-clinical studies are required.

GlobeNewsWire • Nov 4, 2025

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the pricing of its underwritten offering of 40,142,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 5,315,000 shares of common stock.

GlobeNewsWire • Nov 4, 2025

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01

Dr. Kates' experience as chair of the landmark Phase 3 BRIDGE bladder cancer trial and dedication to patient care will be invaluable to the NDV-01 Phase 3 program

GlobeNewsWire • Oct 7, 2025

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement

CORAL GABLES, Fla., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous system indications, today announced that on September 15, 2025 it received written notice from the Nasdaq Stock Market LLC (Nasdaq) confirming that the Company has regained compliance with Nasdaq's $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2) (the “Listing Rule”).

GlobeNewsWire • Sep 16, 2025

Relmada Issues Mid-Year CEO Letter to Shareholders

CORAL GABLES, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous system indications, today issued a Letter to Shareholders from Sergio Traversa, Chief Executive Officer.

GlobeNewsWire • Sep 10, 2025

Relmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call Transcript

Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Maged S. Shenouda - Chief Financial Officer Raj S.

Seeking Alpha • Aug 8, 2025